Redeye: Elicera Therapeutics - On the right path
Redeye revisits some assumptions related to financing and likelihood of approval following the progress with the CARMA study and the recent share price development, leading to a raised valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/